MersV1, PubMed, Corpus, bibRecord, 001157

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.

Identifieur interne : 001157 ( PubMed/Corpus ); précédent : 001156; suivant : 001158

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.

Auteurs : Jean-François Rossignol

Source :

Journal of infection and public health [ 1876-035X ]

RBID : pubmed:27095301

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Clinical Trials as Topic, Coronavirus Infections (drug therapy), Disease Models, Animal, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (physiology), Thiazoles (pharmacology), Thiazoles (therapeutic use), Virus Replication (drug effects).
MESH :
- chemical , pharmacology : Antiviral Agents, Thiazoles.
- chemical , therapeutic use : Antiviral Agents, Thiazoles.
- drug effects : Middle East Respiratory Syndrome Coronavirus, Virus Replication.
- drug therapy : Coronavirus Infections.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans.

Abstract

Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.

DOI: 10.1016/j.jiph.2016.04.001
PubMed: 27095301

Links to Exploration step

pubmed:27095301

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
<affiliation><nlm:affiliation>Romark Laboratories, L.C., Tampa, FL, United States. Electronic address: jrossignol@romark.com.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2016 May-Jun</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:27095301</idno>
<idno type="pmid">27095301</idno>
<idno type="doi">10.1016/j.jiph.2016.04.001</idno>
<idno type="wicri:Area/PubMed/Corpus">001157</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001157</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
<affiliation><nlm:affiliation>Romark Laboratories, L.C., Tampa, FL, United States. Electronic address: jrossignol@romark.com.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of infection and public health</title>
<idno type="eISSN">1876-035X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (physiology)</term>
<term>Thiazoles (pharmacology)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Clinical Trials as Topic</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27095301</PMID>
<DateCompleted><Year>2017</Year>
<Month>01</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-035X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>9</Volume>
<Issue>3</Issue>
<PubDate><MedlineDate>2016 May-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Journal of infection and public health</Title>
<ISOAbbreviation>J Infect Public Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>227-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiph.2016.04.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1876-0341(16)30018-1</ELocationID>
<Abstract><AbstractText>Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals. </AbstractText>
<CopyrightInformation>Copyright © 2016 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rossignol</LastName>
<ForeName>Jean-François</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>Romark Laboratories, L.C., Tampa, FL, United States. Electronic address: jrossignol@romark.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>04</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Infect Public Health</MedlineTA>
<NlmUniqueID>101487384</NlmUniqueID>
<ISSNLinking>1876-0341</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>SOA12P041N</RegistryNumber>
<NameOfSubstance UI="C041747">nitazoxanide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">MERS-CoV</Keyword>
<Keyword MajorTopicYN="N">Nitazoxanide</Keyword>
<Keyword MajorTopicYN="N">Treatment</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>03</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>03</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>04</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>1</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27095301</ArticleId>
<ArticleId IdType="pii">S1876-0341(16)30018-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.jiph.2016.04.001</ArticleId>
<ArticleId IdType="pmc">PMC7102735</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antiviral Res. 2015 Feb;114:1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25451075</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):1061-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25451059</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Int J Infect Dis. 2015 Nov;40:71-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26365771</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Jul;14(7):609-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24852376</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2009 Oct 23;284(43):29798-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19638339</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Int Immunopharmacol. 2012 May;13(1):23-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22430099</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2014 Oct;110:94-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25108173</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2012;8(5):e1002691</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22589723</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001157 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001157 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:27095301
   |texte=   Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:27095301" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki